-DOCSTART- -X- O
Respiratory -X- _ B-Intervention
virus -X- _ I-Intervention
infections -X- _ I-Intervention
in -X- _ O
hematopoietic -X- _ B-Patient
cell -X- _ I-Patient
transplant -X- _ I-Patient
( -X- _ I-Patient
HCT -X- _ I-Patient
) -X- _ I-Patient
recipients -X- _ I-Patient
are -X- _ O
a -X- _ O
major -X- _ O
cause -X- _ B-Outcome
of -X- _ I-Outcome
morbidity -X- _ I-Outcome
and -X- _ I-Outcome
mortality. -X- _ I-Outcome
While -X- _ O
respiratory -X- _ B-Intervention
syncytial -X- _ I-Intervention
virus -X- _ I-Intervention
( -X- _ I-Intervention
RSV -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
human -X- _ I-Intervention
metapneumonvirus -X- _ I-Intervention
, -X- _ I-Intervention
parainfluenzaviruses -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
influenza -X- _ I-Intervention
viruses -X- _ I-Intervention
are -X- _ O
well -X- _ O
known -X- _ O
for -X- _ O
their -X- _ O
potential -X- _ O
to -X- _ O
cause -X- _ O
fatal -X- _ O
pneumonia -X- _ O
, -X- _ O
information -X- _ O
is -X- _ O
emerging -X- _ O
only -X- _ O
recently -X- _ O
on -X- _ O
the -X- _ O
significance -X- _ O
of -X- _ O
the -X- _ O
newly -X- _ O
discovered -X- _ O
viruses -X- _ O
such -X- _ O
as -X- _ O
human -X- _ B-Intervention
coronaviruses -X- _ I-Intervention
NL63 -X- _ I-Intervention
and -X- _ I-Intervention
HKU1 -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
human -X- _ I-Intervention
bocavirus. -X- _ I-Intervention
Lymphopenia -X- _ B-Outcome
seems -X- _ O
to -X- _ O
be -X- _ O
the -X- _ O
most -X- _ O
recent -X- _ O
risk -X- _ O
factors -X- _ O
for -X- _ O
progression -X- _ B-Outcome
to -X- _ I-Outcome
lower -X- _ I-Outcome
respiratory -X- _ I-Outcome
tract -X- _ I-Outcome
disease. -X- _ I-Outcome
Airflow -X- _ I-Outcome
obstruction -X- _ I-Outcome
is -X- _ O
another -X- _ O
complication -X- _ O
of -X- _ O
respiratory -X- _ O
virus -X- _ O
infections -X- _ O
after -X- _ O
HCT -X- _ O
, -X- _ O
and -X- _ O
data -X- _ O
to -X- _ O
date -X- _ O
indicate -X- _ O
this -X- _ O
complication -X- _ O
may -X- _ O
occur -X- _ O
following -X- _ O
parainfluenza -X- _ B-Intervention
virus -X- _ I-Intervention
and -X- _ I-Intervention
RSV -X- _ I-Intervention
infection. -X- _ I-Intervention
Infection -X- _ O
control -X- _ O
procedures -X- _ O
are -X- _ O
key -X- _ O
for -X- _ O
prevention. -X- _ O
Unfortunately -X- _ O
, -X- _ O
there -X- _ O
are -X- _ O
no -X- _ O
randomized -X- _ O
treatment -X- _ O
studies -X- _ O
, -X- _ O
which -X- _ O
make -X- _ O
the -X- _ O
interpretation -X- _ O
of -X- _ O
the -X- _ O
literature -X- _ O
on -X- _ O
interventions -X- _ O
difficult. -X- _ O
This -X- _ O
article -X- _ O
reviews -X- _ O
the -X- _ O
spectrum -X- _ O
of -X- _ O
pathogens -X- _ O
, -X- _ O
epidemiology -X- _ O
, -X- _ O
risk -X- _ O
factors -X- _ O
and -X- _ O
clinical -X- _ O
manifestations -X- _ O
of -X- _ O
infection -X- _ O
, -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
recent -X- _ O
advances -X- _ O
in -X- _ O
diagnostic -X- _ O
and -X- _ O
clinical -X- _ O
management -X- _ O
. -X- _ O

